PROSTATENOW™  Clinical publications

Clinical Evidence

The technology powering PROSTATENOW™ – clinically valid and utilized

The clinical validity and utility of RPMs and GRS in cancer risk assessment – key technology components of PROSTATENOW™ – are supported by hundreds of peer-reviewed papers published by the NorthShore team, including the following key publications in leading journals.

Group-86900@2x

Published: Nov. 28, 2020

Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality

Article Conclusion:

This population-based prospective study suggests that GRS complements two guideline-recommended inherited risk measures (FH and RPMs) for stratifying the risk of PCa incidence and mortality.

Authors:

Zhuqing Shi, Elizabeth A Platz, Jun Wei, Rong Na, Richard J Fantus, Chi-Hsiung Wang, Scott E Eggener, Peter J Hulick, David Duggan, S Lilly Zheng, Kathleen A Cooney, William B Isaacs, Brian T Helfand, Jianfeng Xu

Published: Dec. 27, 2019
Single-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis

Article Conclusion:
This study suggests that a GRS is significantly associated with patient age at PCa diagnosis. Combining FH and GRS may better stratify inherited risk than FH alone for developing personalized PCa screening strategies.

Published: Jan. 12, 2012
Germline Mutations in HOXB13 and Prostate-Cancer Risk

Article Conclusion:
The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer. Although the variant accounts for a small fraction of all prostate cancers, this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer. (Funded by the National Institutes of Health and others.)

Published: Feb. 28, 2008
Cumulative Association of Five Genetic Variants with Prostate Cancer

Article Conclusion:
This study suggests that a GRS is significantly associated with patient age at PCa diagnosis. Combining FH and GRS may better stratify inherited risk than FH alone for developing personalized PCa screening strategies.